Xylem is trading 4.86% down at $88.35 on October 28, extending its sharp decline after the October 27 earnings release and weaker 2026 adjusted EPS outlook.
- Third-quarter revenue was $2.20 billion; the 2026 adjusted EPS outlook fell to $5.40–$5.45 from $5.55–$5.70.
- Management cited project timing and cautious customer spending; investors focused on the weaker outlook despite strong order activity and margin gains.
- Planned divestitures were announced alongside the results.